Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Secord, AA, Havrilesky, LJ, O'Malley, DM, Bae-Jump, V, Fleming, ND, Broadwater, G, Cohn, DE, and Gehrig, PA. "A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer." Gynecol Oncol 114, no. 3 (September 2009): 442-447.

Full Text

Havrilesky, LJ, Secord, AA, O'Malley, DM, Broadwater, G, Bae-Jump, V, Cohn, DE, and Gehrig, PA. "Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer." Gynecol Oncol 114, no. 2 (August 2009): 279-283.

Full Text

Bernardini, MQ, May, T, Khalifa, MA, Bland, AE, Nofech-Mozes, S, Berchuck, A, Covens, A, and Havrilesky, L. "Evaluation of two management strategies for preoperative grade 1 endometrial cancer." Obstet Gynecol 114, no. 1 (July 2009): 7-15.

Full Text

Havrilesky, LJ, Maxwell, GL, and Myers, ER. "Cost-effectiveness analysis of annual screening strategies for endometrial cancer." Am J Obstet Gynecol 200, no. 6 (June 2009): 640.e1-640.e8.

Full Text

Fader, AN, Drake, RD, O'Malley, DM, Gibbons, HE, Huh, WK, Havrilesky, LJ, Gehrig, PA, Tuller, E, Axtell, AE, Zanotti, KM, and Uterine Papillary Serous Carcinoma (UPSC) Consortium, . "Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma." Cancer 115, no. 10 (May 15, 2009): 2119-2127.

Full Text

Wu, JM, Siddiqui, NY, Amundsen, CL, Myers, ER, Havrilesky, LJ, and Visco, AG. "Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence." J Urol 181, no. 5 (May 2009): 2181-2186.

Full Text

Havrilesky, LJ, Broadwater, G, Davis, DM, Nolte, KC, Barnett, JC, Myers, ER, and Kulasingam, S. "Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment." Gynecol Oncol 113, no. 2 (May 2009): 216-220.

Full Text

Alvarez Secord, A, Bae-Jump, V, Havrilesky, LJ, Calingaert, B, Clarke-Pearson, DL, Soper, JT, and Gehrig, PA. "Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists." Int J Gynecol Cancer 19, no. 3 (April 2009): 447-454.

Full Text

Havrilesky, LJ, Maxwell, GL, Chan, JK, and Myers, ER. "Cost effectiveness of a test to detect metastases for endometrial cancer." Gynecol Oncol 112, no. 3 (March 2009): 526-530.

Full Text

Rubatt, JM, Darcy, KM, Hutson, A, Bean, SM, Havrilesky, LJ, Grace, LA, Berchuck, A, and Secord, AA. "Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study." Gynecol Oncol 112, no. 3 (March 2009): 469-474.

Full Text

Pages